Novartis offers payment plan for high-cost heart medicine

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uDFQsO8
via IFTTT